AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$LQDA

JEFFS ROGER sold $400K of LQDA (indirect holdings)

JEFFS ROGER (Chief Executive Officer) sold 6,428 indirectly-held shares of Liquidia Corp (LQDA) at $62.18 ($0.40M total) on 2026-05-27 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · JEFFS ROGER
Published May 28, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 8:41 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$LQDA
Neutral
medium confidence
Mentioned
$LQDA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDANeutralLow
01

Why it matters

Traders may briefly reassess sentiment around insider behavior, but the disclosure does not include new operational, financial, or regulatory information.

02

Market read

A fresh Form 4 provides a new, dated insider sale, but it is typically not a standalone catalyst for repricing fundamentals.

03

What to watch

Indirect holdings and the post-sale share count (1,041,667) may matter more than the sale size; without context on prior plans, the signal is weak.

Relevance 3/10Novelty 5/10Timing: filed 2026-05-28, transaction dated 2026-05-27

Background

The filing is an SEC Form 4 insider transaction by Liquidia’s CEO, reported as an open-market sale with a stated 10b5-1 plan.

Company-level read

Ticker impact

$LQDANeutralMedium confidence
Context

Liquidia CEO Jeffs Roger sold 6,428 shares in an open-market transaction for about $399,712, under a 10b5-1 plan.

Expected impact

Likely limited, short-lived impact unless paired with other negative company-specific news.

Evidence & confidence

Form 4 provides a new, time-stamped transaction and confirms a pre-arranged 10b5-1 plan, which typically reduces signaling risk versus discretionary sales.

Market effects

Sector

No clear sector read-through from a single 10b5-1 insider sale.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect routine liquidity needs rather than bearish expectations.

Key entities

  • issuer
    Liquidia Corp

    Company whose CEO insider sale is disclosed on SEC Form 4.

  • insider
    Jeffs Roger

    CEO and director who sold shares under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

LQDA insider trading history →

Related articles

$LQDAMed

LQDA Q3 Earnings Beat Estimates on Robust Yutrepia Sales

Liquidia Corporation (LQDA) reported Q3 2026 earnings of 80 cents per share, exceeding estimates. Revenue surged 314.6% YoY to $225.3M, driven by strong Yutrepia sales. The company settled litigation with United Therapeutics, incurring a $389.7M charge. LQDA stock gained 7.37% post-announcement. Management remains optimistic about Yutrepia's growth and pipeline advancements.

zacks.com
$LQDAMed

Wells Fargo raises Liquidia stock price target on improved outlook

Wells Fargo raised its price target for Liquidia Technologies (LQDA) to $40 from $33, citing improved demand outlook. The stock has gained 85% over the past year. LQDA reported Q3 revenue of $225.3M, beating estimates, but posted a GAAP EPS loss of $2.64 due to a settlement charge. Analysts from BTIG and Jefferies also raised their price targets, expressing confidence in the company's growth prospects.

investing.com
$LQDAHighAI 8/10

Liquidia (LQDA) Q3 2026 Earnings Call Transcript

Liquidia (LQDA) reported Q3 2026 net product sales of $222.7M, up 31%. PAH diagnoses drove growth, with 70% of prescriptions in September. October saw record shipments post-settlement. Referrals held steady, and prescriber base expanded. YUTREPIA's flexibility supports market share gains in PAH. Financials show strong revenue growth, with adjusted EBITDA at $140.5M. The company plans to fund operations without raising capital.

finance.yahoo.com
$LQDAMed

Liquidia Q3 Earnings Call Highlights

Liquidia (LQDA) reported Q3 adjusted EBITDA of $140.5M, up sequentially, with $396.1M in cash. The company faces a $389.7M settlement, payable by April 2027. Liquidia plans clinical trials for YUTREPIA and L606, with data expected in 2027-2029. Management affirmed no capital raise is needed and no royalties to United Therapeutics post-settlement.

finance.yahoo.com